Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of cepharanthine in preparing medicine for resisting SARS virus

A technology of SARS virus and fenugreek can be used in antiviral agents, drug combinations, pharmaceutical formulations, etc., and can solve problems such as anti-SARS virus drugs that have not yet been seen

Inactive Publication Date: 2003-11-05
GUANGZHOU JINAN BIOMEDICINE RES & DEV CENT
View PDF0 Cites 13 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

The omega interferon developed by the Academy of Military Medical Sciences in China has been identified as an adjuvant drug for the treatment of SARS. There are 19 kinds of drugs with anti-SARS virus activity, but there is no report on the results of in vitro cell experiments on anti-SARS virus drugs

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of cepharanthine in preparing medicine for resisting SARS virus
  • Application of cepharanthine in preparing medicine for resisting SARS virus
  • Application of cepharanthine in preparing medicine for resisting SARS virus

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0035] 1. Experimental material The drug to be tested is patinol, which is made into a suspension with physiological saline during the experiment for experimental use.

[0036] 2. Experimental animals Kunming mice, body weight (20±2) g; Wistar rats, body weight (270±20) g; C57BL / 6 mice, body weight (20±2) g.

[0037] 3. Acute and chronic toxicity test of oral gavage administration ① Determination of acute toxicity (LD50) and maximum tolerated dose in mice: 30 animals that had been fasted for 12 hours in advance were randomly divided into 3 groups, 10 in each group , the distance between each dose group was 0.85. The stephenicine was made into concentrations of (2.0, 1.7, 1.4%) respectively, and then the animals were given 0.4ml·10g-1 body weight, 1 time ig, the maximum dose was 800mg·kg-1, observed for 1 week, and the general condition of all animals Good, without any toxic reaction and death. On this basis, carry out the maximum tolerance test within 1 day; take another 20 ...

Embodiment 2

[0039] In the clinical trial conducted on human beings, the test group took medication, and the usage and dosage of Stephania injection: 50 mg once a day, slowly intravenously drip. The control group injected normal saline, its state of illness is as shown in table 3, and the healing time is as shown in table 4:

[0040] group

[0041] group

[0042] Note: The numbers in () are the death toll. The results in this table show that the treatment time of the patients in the test group (that is, the RD-01 treatment group) is significantly shortened compared with that in the control group.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
concentrationaaaaaaaaaa
Login to View More

Abstract

Cepharanthine is used as effective component in preparing medicine for resisting SARS virus. Within the safe dosage range, the present invention has high inhibition rate to SARS virus and powerful effect of preventing SARS virus infection. The medicine can alleviate the syndromes of SARS patient and has fast after cure, less toxicity, high stability and other advantages.

Description

technical field [0001] The present invention relates to the field of medicines, in particular to the application of stepherin in the preparation of anti-SARS virus medicines. Background technique [0002] Since the formal identification of the pathogen of atypical pneumonia as the SARS coronavirus, great progress has been made in the prevention and research of atypical pneumonia and its pathogen, and the development of anti-SARS coronavirus drugs and vaccines is also in full swing. SARS virus is a new type of coronavirus with strong infectivity and variability. At present, there is still a lack of effective treatment for SARS. The current treatment includes antiviral treatment such as ribavirin, serum therapy, etc., hormones are used to reduce the damage of the immune system to the lungs, antibiotics are used to treat potential bacterial infections, and syndrome differentiation of integrated traditional Chinese and Western medicine; The application of ventilator and the sym...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/4741A61P11/00A61P31/14
Inventor 王一飞李久香王庆瑞杨崇文陆家海刘新建
Owner GUANGZHOU JINAN BIOMEDICINE RES & DEV CENT
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products